Breaking News, Collaborations & Alliances

Batavia and Candel Partner to Accelerate Development of CAN-3110

Aim to advance and accelerate the development of treatments for recurrent high-grade glioma.

Author Image

By: Charlie Sternberg

Associate Editor

Batavia Biosciences, a contract development and manufacturing organization, has partnered with Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).   Batavia Biosciences will use its HIP-Vax technology to develop...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters